271 related articles for article (PubMed ID: 32975461)
1. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
Taylor HS; Dun EC; Chwalisz K
Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
[TBL] [Abstract][Full Text] [Related]
4. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
[TBL] [Abstract][Full Text] [Related]
6. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
Pokrzywinski RM; Soliman AM; Chen J; Snabes MC; Coyne KS; Surrey ES; Taylor HS
Am J Obstet Gynecol; 2020 Jun; 222(6):592.e1-592.e10. PubMed ID: 31759891
[TBL] [Abstract][Full Text] [Related]
7. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients.
Abrao MS; Surrey E; Gordon K; Snabes MC; Wang H; Ijacu H; Taylor HS
BMC Womens Health; 2021 Jun; 21(1):246. PubMed ID: 34134684
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
[TBL] [Abstract][Full Text] [Related]
9. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
Diamond MP; Carr B; Dmowski WP; Koltun W; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Mar; 21(3):363-71. PubMed ID: 23885105
[TBL] [Abstract][Full Text] [Related]
10. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
Barra F; Scala C; Ferrero S
Drugs Today (Barc); 2019 Apr; 55(4):237-246. PubMed ID: 31050692
[TBL] [Abstract][Full Text] [Related]
11. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
Ezzati M; Carr BR
Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
[TBL] [Abstract][Full Text] [Related]
12. Elagolix for endometriosis: all that glitters is not gold.
Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
[TBL] [Abstract][Full Text] [Related]
13. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
Fantasia HC
Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
[TBL] [Abstract][Full Text] [Related]
14. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
15. An Evidence-Based Review of Elagolix for the Treatment of Pain Secondary to Endometriosis.
Urits I; Adamian L; Miro P; Callan J; Patel PM; Patel M; Berger AA; Kassem H; Kaye AD; Viswanath O
Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):197-215. PubMed ID: 33633426
[TBL] [Abstract][Full Text] [Related]
16. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
[TBL] [Abstract][Full Text] [Related]
17. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
18. Medical therapy options for endometriosis related pain, which is better? A systematic review and network meta-analysis of randomized controlled trials.
Samy A; Taher A; Sileem SA; Abdelhakim AM; Fathi M; Haggag H; Ashour K; Ahmed SA; Shareef MA; AlAmodi AA; Keshta NHA; Shatat HBAE; Salah DM; Ali AS; El Kattan EAM; Elsherbini M
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101798. PubMed ID: 32479894
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of elagolix in the treatment of endometriosis.
Perricos A; Wenzl R
Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
[TBL] [Abstract][Full Text] [Related]
20. Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix.
Agarwal SK; Soliman AM; Pokrzywinski RM; Snabes MC; Coyne KS
J Sex Med; 2020 Dec; 17(12):2427-2433. PubMed ID: 32928659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
